CI

At a glance

ClinicalIndex Comparison Record
Phase 2Unknown· 100 target
Drug / intervention
Docetaxel for injection (Albumin-bound) +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05705635
NCT05705635Phase 2Unknown
CompareCT.gov

A Multicenter, Randomized, Controlled Phase II Clinical Study of Comparison of Docetaxel for Injection (Albumin-bound) and Taxotere in Second-line or Above Locally Advanced or Metastatic Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma

CSPC ZhongQi Pharmaceutical Technology Co., Ltd.·interventional·Posted Jan 31, 2023·Updated Jan 31, 2023

In Brief

A Phase 2 clinical trial evaluating Docetaxel for injection (Albumin-bound) and Taxotere for Gastric Adenocarcinoma and Adenocarcinoma of Gastroesophageal Junction. Targeting 100 participants across 1 site.

Detailed Summary

This trial is a multicenter, randomized, controlled clinical study to evaluate the efficacy and safety of Docetaxel for Injection (Albumin-bound) and Taxotere in locally advanced or metastatic gastric adenocarcinoma or gastroesophageal junction adenocarcinoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsGastric Adenocarcinoma, Adenocarcinoma of Gastroesophageal Junction
CountriesChina
Collaborators--

Timeline

Phase 2UnknownOverdue
2023202420252026
First PostedJan 31, 2023
Enrollment StartJan 13, 2023
Primary CompletionMay 1, 2023
Study CompletionDec 1, 2024
TodayJul 1, 2026
Enrollment to primary: 4 monthsPosted 3.4 years ago

Interventions

Docetaxel for injection (Albumin-bound)drug

Docetaxel for injection (Albumin-bound), by intravenous infusion, every 3 weeks.

Taxoteredrug

Taxotere, by intravenous infusion, every 3 weeks.